We develop innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions.
ONL Therapeutics is a clinical-stage biopharmaceutical company committed to helping patients see the future.
Clinical Trials
The company’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide that is being studied in multiple diseases.
Science
Our primary scientific focus is Fas-mediated signaling, initiated by the activation of the Fas receptor at the cell surface and implicated in a variety of diseases.